MCID: PRS042
MIFTS: 44

Prostate Disease

Categories: Endocrine diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 42 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hypertrophy and prostatic hyperplasia, benign, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3), and among its related pathways/superpathways is Transcription Androgen Receptor nuclear signaling. The drugs Iodine and Povidone have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and testes.

Wikipedia : 74 The prostate is an exocrine gland of the male reproductive system in most mammals. It differs... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 32.2 SRD5A1 KLK3 AR
2 prostatic hyperplasia, benign 32.1 SRD5A1 KLK3 CDKN2B-AS1 AR
3 prostatic adenoma 31.9 SRD5A1 KLK3
4 prostate cancer 31.2 TERC SRD5A1 SCHLAP1 PTENP1 PRNCR1 PCGEM1
5 impotence 31.1 SRD5A1 KLK3 AR
6 suppression of tumorigenicity 12 31.0 PCA3 KLK3 FOLH1 AR
7 bladder cancer 30.6 TERC SCHLAP1 PCAT1 MEG3 MALAT1 H19
8 gynecomastia 30.5 SRD5A1 KLK3 AR
9 alopecia, androgenetic, 1 30.4 SRD5A1 AR
10 renal cell carcinoma, nonpapillary 30.4 SCHLAP1 PTENP1 MALAT1 LINC00963 H19 GAS5
11 prostatitis 11.0
12 prostate neuroendocrine neoplasm 10.8 KLK3 FOLH1 AR
13 androgenic alopecia 10.8 SRD5A1 KLK3 AR
14 sex development disorder 10.8 SRD5A1 KLK3 AR
15 prostate adenoid cystic carcinoma 10.8 KLK3 AR
16 prostate leiomyoma 10.8 KLK3 AR
17 bladder urothelial carcinoma 10.8 SRD5A1 MEG3 MALAT1 KLK3 GAS5 AR
18 thyroid cancer, nonmedullary, 1 10.7 MALAT1 H19 GAS5
19 submandibular gland cancer 10.7 KLK3 AR
20 prostatic acinar adenocarcinoma 10.7 KLK3 AR
21 coronary heart disease 1 10.7 IGF2-AS H19 GAS5 CDKN2B-AS1
22 androgen insensitivity, partial 10.7 SRD5A1 AR
23 glioma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1 CBR3-AS1
24 osteogenic sarcoma 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
25 glioma susceptibility 1 10.7 PCAT1 MEG3 MALAT1 LINC00963 H19 GAS5
26 prostate stromal sarcoma 10.7 PCA3 KLK3
27 osteoarthritis 10.7 PCGEM1 MEG3 H19 GAS5
28 cervical cancer 10.7 TERC PCAT1 MEG3 MALAT1 H19 GAS5
29 malignant glioma 10.7 PRNCR1 PCGEM1 MEG3 MALAT1 LINC00963 H19
30 myeloma, multiple 10.7 PCAT1 MEG3 MALAT1 H19 GAS5
31 astrocytoma 10.7 PCA3 H19 GAS5 CDKN2B-AS1
32 endometrial cancer 10.7 TERC PTENP1 MEG3 KLK3 H19 GAS5
33 gallbladder cancer 10.7 MEG3 MALAT1 H19 CDKN2B-AS1
34 squamous cell carcinoma 10.7 PCAT1 MALAT1 H19 CDKN2B-AS1 CBR3-AS1
35 esophageal cancer 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
36 nasopharyngeal carcinoma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
37 wilms tumor 1 10.6 MEG3 IGF2-AS H19 AR
38 pseudovaginal perineoscrotal hypospadias 10.6 SRD5A1 AR
39 gastric cancer 10.6 TERC PTENP1 PRNCR1 PCAT1 MEG3 MALAT1
40 laryngeal squamous cell carcinoma 10.6 MALAT1 H19 CDKN2B-AS1
41 vulva squamous cell carcinoma 10.6 MEG3 MALAT1
42 kidney cancer 10.6 MEG3 MALAT1 H19 GAS5
43 hepatocellular carcinoma 10.6 TERC PTENP1 PCAT1 MEG3 MALAT1 IGF2-AS
44 polycystic ovary syndrome 10.6 SRD5A1 GAS5 AR
45 withdrawal disorder 10.5 KLK3 AR
46 pituitary adenoma 10.5 MEG3 MALAT1 H19
47 diabetic cataract 10.5 MALAT1 AR
48 villous adenoma 10.4 KLK3 FOLH1
49 meningioma, radiation-induced 10.2 MEG3 H19
50 adenoma 10.1

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


tremor, angina pectoris, equilibration disorder, prostatism

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4 7553-56-2 807
2
Povidone Approved Phase 4 9003-39-8
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
5 Anti-Infective Agents, Local Phase 4
6 Anti-Infective Agents Phase 4
7 Plasma Substitutes Phase 4
8 Blood Substitutes Phase 4
9 cadexomer iodine Phase 4
10 Fenugreek seed meal Phase 4
11 Fenugreek Phase 4
12 Hypoglycemic Agents Phase 4
13
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
14
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
15
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
16 Vasodilator Agents Phase 3
17 Phosphodiesterase Inhibitors Phase 3
18 Phosphodiesterase 5 Inhibitors Phase 3
19 Adrenergic alpha-Antagonists Phase 3
20 Neurotransmitter Agents Phase 3
21 Adrenergic Antagonists Phase 3
22 Adrenergic Agents Phase 3
23 5-alpha Reductase Inhibitors Phase 3
24 Steroid Synthesis Inhibitors Phase 3
25
Ethanol Approved Phase 1, Phase 2 64-17-5 702
26
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
27
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
28
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
29
nivolumab Approved Phase 1, Phase 2 946414-94-4
30
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
31
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
32 Onapristone Investigational Phase 1, Phase 2 96346-61-1
33 Immunologic Factors Phase 1, Phase 2
34 Androgen Antagonists Phase 1, Phase 2
35 Central Nervous System Depressants Phase 1, Phase 2
36 Imatinib Mesylate Phase 2 220127-57-1 123596
37 Protein Kinase Inhibitors Phase 2
38 Vaccines Phase 2
39 Fertility Agents Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Prolactin Release-Inhibiting Factors Phase 2
42 Antibodies, Monoclonal Phase 1, Phase 2
43 Immunoglobulin G Phase 1, Phase 2
44 Antibodies Phase 1, Phase 2
45 Immunoglobulins Phase 1, Phase 2
46 Epothilones Phase 2
47 Antimitotic Agents Phase 2
48 Antineoplastic Agents, Immunological Phase 2
49
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
50 Cola Phase 1

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
3 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00827242 Phase 3 Placebo;tadalafil
5 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
6 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
7 A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. Unknown status NCT00895466 Phase 1, Phase 2
8 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
9 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
10 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
11 A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy Completed NCT01431391 Phase 2 leuprolide acetate
12 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer Recruiting NCT03543189 Phase 1, Phase 2 Nivolumab;Androgen Deprivation Therapy
13 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
14 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
15 A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate Terminated NCT00448097 Phase 2 cetuximab;docetaxel
16 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy Withdrawn NCT03658408 Phase 2 4-aminopyridine;placebo
17 A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy Withdrawn NCT02065323 Phase 2 Standard ADT;Dovitinib
18 Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy Completed NCT01307852 Phase 1
19 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
20 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
21 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
22 Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China Unknown status NCT01590498
23 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Unknown status NCT03192917
24 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) Completed NCT01826617
25 Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00941343 Alfuzosin (XATRAL® - SL770499)
26 Intratesticular Hormone Levels in Healthy Young Men Completed NCT00756561
27 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907
28 Validation of a Semiquantitative Screening Assay for PSA Completed NCT00853710
29 Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy Completed NCT01762241
30 Prostatic Artery Embolization for Benign Prostatic Obstruction Completed NCT03099421
31 Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery Completed NCT00484783
32 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
33 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
34 Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy Completed NCT00407329
35 Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly Completed NCT00616408 Octreotide-LAR
36 2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection Completed NCT01886547
37 Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer Recruiting NCT03350529
38 MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer Recruiting NCT04026763
39 Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging Recruiting NCT03711643
40 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
41 Contrast Enhanced MRI of the Prostate Recruiting NCT02245282
42 Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men Recruiting NCT04134130 Degarelix 120 MG [Firmagon];Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector;Testosterone Undecanoate
43 Biobank for African American Prostate Cancer Research in Florida Recruiting NCT03232411
44 Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease Recruiting NCT04024475
45 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
46 Molecular Studies and Clinical Correlations in Human Prostatic Disease Active, not recruiting NCT00578240
47 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial Enrolling by invitation NCT03589196
48 Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at UCLA Enrolling by invitation NCT03503643
49 A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? Terminated NCT02031029
50 Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer Terminated NCT02307552

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

40
Prostate, Kidney, Testes, Bone, Spinal Cord, Heart, Liver

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 1504)
# Title Authors PMID Year
1
Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. 42
31727627 2019
2
Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial. 42
31702643 2019
3
Re: The Evaluation of Nocturia in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and the Analysis of the Curative Effect after Medical or Placebo Therapy for Nocturia: A Randomized Placebo-Controlled Study. 42
31766084 2019
4
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. 54 61
20351196 2010
5
Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. 54 61
19670261 2010
6
Psychological distress and prostate specific antigen levels in men with and without prostate cancer. 54 61
19486654 2009
7
Biomarkers for prostate cancer. 54 61
19507229 2009
8
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. 54 61
18627423 2009
9
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. 54 61
19375623 2009
10
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. 54 61
19128049 2009
11
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. 54 61
19030020 2009
12
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]. 54 61
19157222 2008
13
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 54 61
18668524 2008
14
5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. 54 61
18320593 2008
15
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. 54 61
18686378 2008
16
A preliminary study of the baboon prostate pathophysiology. 54 61
17639509 2007
17
Androgen receptor modulation: lessons learned from beyond the prostate. 54 61
17881894 2007
18
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. 54 61
17571482 2007
19
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 54 61
17159365 2007
20
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 54 61
17318358 2006
21
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. 54 61
16093978 2005
22
Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. 54 61
15956333 2005
23
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. 54 61
14532846 2003
24
Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. 54 61
12858359 2003
25
Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. 54 61
12962896 2003
26
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. 54 61
11903683 2001
27
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. 54 61
11720279 2001
28
[Urinary problems and prostate-specific antigen in a Norwegian normal population]. 54 61
11301608 2001
29
Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients. 54 61
11741128 2001
30
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. 54 61
11326656 2000
31
Polyarteritis nodosa mimicking prostatic cancer. 54 61
11036851 2000
32
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 54 61
11061535 2000
33
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]. 54 61
11107529 2000
34
Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. 54 61
10750886 2000
35
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. 54 61
10632336 1999
36
Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein. 54 61
10510889 1999
37
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. 54 61
9730460 1998
38
Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer. 54 61
9352130 1997
39
[Influence of age on serum prostate specific antigen concentration]. 54 61
9594181 1996
40
PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. 54 61
8638528 1996
41
Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. 54 61
8977078 1996
42
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. 54 61
7479385 1995
43
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 54 61
8750649 1995
44
Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. 54 61
8725043 1995
45
Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. 54 61
7521173 1994
46
[Variability of values of prostate-specific antigen determined with 6 methods]. 54 61
7514278 1994
47
Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. 54 61
7531895 1994
48
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]. 54 61
7685140 1993
49
[Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. 54 61
1721770 1991
50
[A mass screening of the prostatic diseases and serum prostate specific antigen]. 54 61
1720276 1991

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

Pathways related to Prostate Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.96 SRD5A1 KLK3 AR

GO Terms for Prostate Disease

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sex differentiation GO:0007548 9.16 SRD5A1 AR
2 regulation of systemic arterial blood pressure GO:0003073 8.96 KLK3 AR
3 cellular response to testosterone stimulus GO:0071394 8.62 SRD5A1 AR

Sources for Prostate Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....